EuroPCR, 21-24 May 2019, Paris, France
by Siemens Healthineers and Mentice | May 22, 2019
Not for publication in the USA
- The novel integrated simulation solution offers an opportunity for clinicians to explore a new minimally-invasive therapy.
- Live at EuroPCR2019 on May 22 at 3:00pm, Siemens Healthineers booth #58, Level 2.
At EuroPCR 2019, Mentice AB, a world leader in simulation solutions for endovascular therapies, and Siemens Healthineers, a leading medical technology company, jointly demonstrate a virtual tricuspid valve reconstruction. For the first time, symposium visitors will have the opportunity to experience the live repair of a leaking tricuspid valve on a virtual patient within the angio-suite with the help of Edwards CardiobandTM Tricuspid Valve Reconstruction System, using Mentice VIST® Virtual Patient as integrated in the newly launched angiography system from Siemens Healthineers, the Artis icono cardiovascular edition.
As the field of cardiovascular intervention is evolving rapidly, new minimally invasive procedures and techniques emerge while patient diversity and complex, varied diseases create additional challenges. With the integration of the Mentice VIST® Virtual Patient and Edwards CardiobandTM Tricuspid Valve Reconstruction System into the Artis icono cardiovascular edition from Siemens Healthineers, the solution offers interventional cardiologists the opportunity to experience a new transcatheter therapy for the treatment of tricuspid valve diseases, contributing to a comprehensive training program for enhancing care of heart patients.
The most common disease of the tricuspid valve is the tricuspid valve insufficiency. In most cases, the leakage of the valvular cusps between the right atrium and the right ventricle is caused by a pre-existing disease of the heart valves in the left heart. A clinically relevant tricuspid valve insufficiency mainly occurs in old age and is expected to occur more frequently due to global and regional demographic changes.
“In the case of severe tricuspid valve insufficiency, surgery has been the gold standard so far. However, various new interventional therapy methods for the tricuspid valve insufficiency are in clinical trials, such as the Edwards CardiobandTMTricuspid Valve Reconstruction System. Currently, available data demonstrate that the new interventional therapies are safe and can improve patient outcomes. If clinicians can practice new therapy methods on virtual patients in a realistic environment while handling the actual medical devices, this would be the best prerequisite for a successful application on real patients,” says PD Dr. Martin Arnold, interventional cardiologist at the University of Erlangen, Germany.
“The outlook for new interventional therapies like Edwards CardiobandTM Tricuspid Valve Reconstruction System is impressive compelling us to deliver new and innovative solutions to health systems that help improve acquisition and retention of skills, drive productivity, and ultimately help improve patient outcomes. Our ability to deliver a virtual patient into the angio-suite through the integration of our VIST® Virtual Patient with the Siemens Healthineers Artis icono angiography system is now allowing physicians and teams around the world to safely acquire new skills, plan, rehearse and retain skills in a realistic and safe for the patient and the physician environment,” said Göran Malmberg CEO of Mentice.
“The integrated solution for virtual cases with Edwards CardiobandTM Tricuspid Valve Reconstruction System and Mentice VIST®Virtual Patient demonstrates how the collaboration of Siemens Healthineers with its partners in the medical industry is helping cardiovascular care clinicians in their efforts to innovate minimally invasive therapies and improve outcomes for patients,” says Doris Pommi, head of cardiology at Siemens Healthineers.
The Artis icono and its functions are not available in all countries. Their future availability cannot be ensured. The Artis icono is not for sale in the U.S.
Siemens Healthineers enables healthcare providers worldwide to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging, and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. In fiscal 2018, which ended on September 30, 2018, Siemens Healthineers generated revenue of €13.4 billion and adjusted profit of €2.3 billion and has about 50,000 employees worldwide. Further information is available at www.siemens-healthineers.com.
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at:
For more information,
Stacy Hammar, Marketing Communication Manager, EMEA at +46 (0) 31 339 94 94, firstname.lastname@example.org
Phone: +49 174 9351391;